Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: An unusually high prevalence of ras mutations

American Journal of Clinical Pathology

Volumn 120, Issue 1, 2003, Pages 71-77

  Zhu, Zhaowen ^a   Gandhi, Manoj ^a   Nikiforova, Marina N ^a   Fischer, Andrew H ^b   Nikiforov, Yuri E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Follicular variant; Papillary thyroid carcinoma; PAX8 PPAR rearrangement; Ras mutations; Ret PTC rearrangement

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; CELL RECEPTOR; DNA; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CANCER INVASION; CELL ENCAPSULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOLOGY; DNA FINGERPRINTING; FEMALE; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; ONCOGENE RAS; ONCOGENE RET; PAPILLARY THYROID CARCINOMA GENE; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA; GENETICS; METABOLISM; METASTASIS; PAPILLARY CARCINOMA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID FOLLICULAR CARCINOMA; THYROID TUMOR;

ADULT; CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENE REARRANGEMENT; GENES, RAS; HUMANS; MALE; NUCLEAR PROTEINS; PAIRED BOX TRANSCRIPTION FACTORS; POINT MUTATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 85047687680     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/ND8D9LAJTRCTG6QD     Document Type: Article

References (43)

1. Lindsay S. Carcinoma of the Thyroid Gland: A Clinical and Pathologic Study of 293 Patients at the University of California Hospital. Springfield, IL: Charles C Thomas; 1960.
2. Chen KT, Rosai J. Follicular variant of thyroid papillary carcinoma: a clinicopathologic study of six cases. Am J Surg Pathol. 1977;1:123-130.
3. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the Thyroid Gland. Washington, DC: Armed Forces Institute of Pathology; 1992. Atlas of Tumor Pathology; Third Series, Fascicle 5.
4. LiVolsi VA. Surgical Pathology of the Thyroid. Philadelphia, PA: Saunders; 1990.
5. Rosai J, Zampi G, Carcangiu ML. Papillary carcinoma of the thyroid: a discussion of its several morphologic expressions, with particular emphasis on the follicular variant. Am J Surg Pathol. 1983;7:809-817.
6. Tickoo SK, Pittas AG, Adler M, et al. Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med. 2000;124:1440-1447.
7. Smallridge RC, Castro MR, Morris JC, et al. Renal metastases from thyroid papillary carcinoma: study of sodium iodide symporter expression. Thyroid. 2001;11:795-804.
8. Loureiro MM, Leite VH, Boavida JM, et al. An unusual case of papillary carcinoma of the thyroid with cutaneous and breast metastases only. Eur J Endocrinol. 1997;137:267-269.
9. Baloch ZW, LiVolsi VA. Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. Mod Pathol. 2000;13:861-865.
10. Chan JK. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma [editorial]. Am J Clin Pathol. 2002;117:16-18.
11. Williams ED. Guest Editorial: Two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol. 2000;8:181-183.
12. Baloch ZW, Gupta PK, Yu GH, et al. Follicular variant of papillary carcinoma: cytologic and histologic correlation. Am J Clin Pathol. 1999;111:216-222.
13. Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002;117:143-150.
14. Renshaw AA, Gould EW. Why there is the tendency to "overdiagnose" the follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2002;117:19-21.
15. Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998;4:287-294.
16. Jhiang SM, Caruso DR, Gilmore E, et al. Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene. 1992;7:1331-1337.
17. Santoro M, Carlomagno F, Hay ID, et al. ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest. 1992;89:1517-1522.
18. Lam AK, Montone KT, Nolan KA, et al. ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Hum Pathol. 1998;29:565-568.
19. Sugg SL, Ezzat S, Zheng L, et al. Oncogene profile of papillary thyroid carcinoma. Surgery. 1999;125:46-52.
20. Bongarzone I, Vigneri P, Mariani L, et al. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res. 1998;4:223-228.
21. Nikiforova MN, Caudill CM, Biddinger P, et al. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol. 2002;10:15-22.
22. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgammal fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000;289:1357-1360.
23. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26:1016-1023.
24. Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002;87:3947-3952.
25. Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. 1989;4:159-164.
26. Suarez HG, du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene. 1990;5:565-570.
27. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol. 1990;4:1474-1479.
28. Shi YF, Zou MJ, Schmidt H, et al. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res. 1991;51:2690-2693.
29. Esapa CT, Johnson SJ, Kendall-Taylor P, et al. Prevalence of ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999;50:529-535.
30. Motoi N, Sakamoto A, Yamochi T, et al. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract. 2000;196:1-7.
31. Lemoine NR, Mayall ES, Wyllie FS, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988;48:4459-4463.
32. Karga H, Lee JK, Vickery AL Jr, et al. ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991;73:832-836.
33. Manenti G, Pilotti S, Re FC, et al. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer. 1994;30A:987-993.
34. Hara H, Fulton N, Yashiro T, et al. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery. 1994;116:1010-1016.
35. Ezzat S, Zheng L, Kolenda J, et al. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid. 1996;6:409-416.
36. Basolo F, Pisaturo F, Pollina LE, et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid. 2000;10:19-23.
37. Nikiforov YE, Nikiforova MN, Gnepp DR, et al. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene. 1996;13:687-693.
38. Argani P, Zakowski MF, Klimstra DS, et al. Detection of the SYT-SSX chimeric RNA of synovial sarcoma in paraffin-embedded tissue and its application in problematic cases. Mod Pathol. 1998;11:65-71.
39. Nikiforova MN, Lynch RA, Biddinger PW, et al. ras point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. In press.
40. Tielens ET, Sherman SI, Hruban RH, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study. Cancer. 1994;73:424-431.
41. Jain M, Khan A, Patwardhan N, et al. Follicular variant of papillary thyroid carcinoma: a comparative study of histopathologic features and cytology results in 141 patients. Endocr Pract. 2001;7:79-84.
42. Smit JW, Van Zelderen-Bhola S, Merx R, et al. A novel chromosomal translocation t(3;5) (q12;p15.3) and loss of heterozygosity on chromosome 22 in a multifocal follicular variant of papillary thyroid carcinoma presenting with skin metastases. Clin Endocrinol (Oxf). 2001;55:543-548.
43. Perissel B, Coupier I, De Latour M, et al. Structural and numerical aberrations of chromosome 22 in a case of follicular variant of papillary thyroid carcinoma revealed by conventional and molecular cytogenetics. Cancer Genet Cytogenet. 2000;121:33-37.